Thymosin α1 is a peptide fragment derived from prothymosin alpha, a protein that in humans is encoded by the PTMA gene.
It was the first of the peptides from Thymosin Fraction 5 to be completely sequenced and synthesized. Unlike β thymosins, to which it is genetically and chemically unrelated, thymosin α1 is produced as a 28-amino acid fragment, from a longer, 113-amino acid precursor, prothymosin α.
Based on the Thymosin Alpha-1 market development status, competitive landscape and development model in different regions of the world, this report is dedicated to providing niche markets, potential risks and comprehensive competitive strategy analysis in different fields. From the competitive advantages of different types of products and services, the development opportunities and consumption characteristics and structure analysis of the downstream application fields are all analyzed in detail. To Boost Growth during the epidemic era, this report analyzes in detail for the potential risks and opportunities which can be focused on.

In Chapter 2.4 of the report, we share our perspectives for the impact of COVID-19 from the long and short term.
In chapter 3.4, we provide the influence of the crisis on the industry chain, especially for marketing channels.
In chapters 8-13, we update the timely industry economic revitalization plan of the country-wise government.

Key players in the global Thymosin Alpha-1 market covered in Chapter 5:
Zadzxin
Suzhou Tianma Pharma Group Tianji Bio-Pharmaceutical Co., Ltd.
Manus Aktteva Biopharma LLP
Hainan Zhonghe Pharmaceutical Co., Ltd.
Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Harbin Pharmaceutical Group Bio-Engineering Co., Ltd.
SPH No. 1 Biochemical & Pharmaceutical Co., Ltd.
Chengdu Shengnuo Biopharm Co., Ltd.

In Chapter 6, on the basis of types, the Thymosin Alpha-1 market from 2015 to 2025 is primarily split into:
1g
5g
10g
50g
Others

In Chapter 7, on the basis of applications, the Thymosin Alpha-1 market from 2015 to 2025 covers:
Chronic Hepatitis B
Acute Severe Hepatitis
Adjuvant Therapy for Tumor
Immuno Compromised Diseases
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 8-13:
North America (Covered in Chapter 9)
United States
Canada
Mexico
Europe (Covered in Chapter 10)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 11)
China
Japan
South Korea
Australia
India
South America (Covered in Chapter 12)
Brazil
Argentina
Columbia
Middle East and Africa (Covered in Chapter 13)
UAE
Egypt
South Africa

Years considered for this report:

Historical Years:

2015-2019

Base Year:

2019

Estimated Year:

2020

Forecast Period:

2020-2025